June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Towards in vivo molecular imaging of the retina: OCT-guided Raman spectroscopy
Author Affiliations & Notes
  • Ryan Sentosa
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Clara Stiebing
    Leibniz Institute of Photonic Technology (Leibniz-IPHT), Jena, Thüringen, Germany
  • Matthias Eibl
    Carl Zeiss Meditec AG, Jena, Thüringen, Germany
  • Milana Kendrisic
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Matthias Salas
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Wim de Jong
    TNO, Delft, South Holland, Netherlands
  • Michael Schmitt
    Leibniz Institute of Photonic Technology (Leibniz-IPHT), Jena, Thüringen, Germany
  • Jason Ensher
    Insight Photonic Solutions, Inc., Lafayette, Colorado, United States
  • Bernhard Baumann
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Andreas Pollreisz
    Department of Ophthalmology, Medical University of Vienna, Vienna, Vienna, Austria
  • Arjen Amelink
    TNO, Delft, South Holland, Netherlands
  • Michael Kempe
    Carl Zeiss Meditec AG, Jena, Thüringen, Germany
  • Tilman Schmoll
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Wolfgang Drexler
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Jürgen Popp
    Leibniz Institute of Photonic Technology (Leibniz-IPHT), Jena, Thüringen, Germany
  • Rainer A Leitgeb
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships   Ryan Sentosa Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor); Clara Stiebing None; Matthias Eibl Carl Zeiss Meditec AG, Code E (Employment); Milana Kendrisic Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor); Matthias Salas None; Wim de Jong None; Michael Schmitt None; Jason Ensher Insight Photonic Solutions, Inc., Code E (Employment); Bernhard Baumann None; Andreas Pollreisz None; Arjen Amelink None; Michael Kempe Carl Zeiss Meditec AG, Code E (Employment); Tilman Schmoll Carl Zeiss Meditec, Inc., Code E (Employment); Wolfgang Drexler Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor), Carl Zeiss Meditec, Inc., Code F (Financial Support); Jürgen Popp None; Rainer Leitgeb Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor), Carl Zeiss Meditec, Inc., Code F (Financial Support)
  • Footnotes
    Support  This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732969 (MOON). It is an initiative of the Photonics Public Private Partnership. www.photonics21.org
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryan Sentosa, Clara Stiebing, Matthias Eibl, Milana Kendrisic, Matthias Salas, Wim de Jong, Michael Schmitt, Jason Ensher, Bernhard Baumann, Andreas Pollreisz, Arjen Amelink, Michael Kempe, Tilman Schmoll, Wolfgang Drexler, Jürgen Popp, Rainer A Leitgeb; Towards in vivo molecular imaging of the retina: OCT-guided Raman spectroscopy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2918.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Optical coherence tomography (OCT) has been extensively used for visualizing the structure and vasculature of the human retina, however, it does not provide molecular information, which might be relevant for early diagnostic purposes. Here we investigated the potential diagnostic capability of in vivo Raman spectroscopy (RS) of the retina in a clinical setting.

Methods : 10 human subjects with age-related macular degeneration (AMD) and 10 healthy controls were imaged by using a custom-built multimodal ophthalmic imaging device, combining IR fundus imaging, swept source (SS)-OCT and RS, covering an area of 18 x 18 mm2 across the retina. The IR fundus imaging is operated at 730 nm. The OCT system is operated at 1060 nm with 100 kHz A-scan rate. The generated OCT en face image was used as a guidance to select the position for performing the RS measurement (operating at 785 nm). Each RS measurement was set to 3x20s as a compromise between signal to noise ratio and subject comfort. 40 Raman spectra were collected, 20 spectra for each group (AMD or Healthy). The processed Raman spectra were then analyzed using multivariate analysis.

Results : The IR fundus images and the corresponding en face projection images of the OCT data from a healthy subject and an AMD patient are shown in Figure 1a and 1b and in Figure 1d and 1e, respectively. Figure 1c and 1f show the mean and standard deviation of the Raman spectra of the healthy group and the AMD group, respectively. The blue and red arrows in the figure indicate the location of the RS measurement (around the peripapillary area). The RS analysis based on principal component analysis (PCA) yields a sensitivity of 100% and a specificity of 95%.

Conclusions : With our multimodal ophthalmic imaging device, we can acquire interpretable Raman spectra from AMD subjects and healthy controls. Our results confirmed the potential of RS to differentiate healthy and diseased retina tissue in vivo. In future clinical studies, we will investigate that the molecular information obtained by RS could enable an earlier diagnosis of retina diseases.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1. Measurement results, a) and d) IR fundus image, b) and e) OCT en face projection, c) and f) mean and standard deviation of the Raman spectra (10 subjects from each group). Top row: healthy control. Bottom row: AMD subject. Scale bar: 1 mm

Figure 1. Measurement results, a) and d) IR fundus image, b) and e) OCT en face projection, c) and f) mean and standard deviation of the Raman spectra (10 subjects from each group). Top row: healthy control. Bottom row: AMD subject. Scale bar: 1 mm

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×